News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Pfizer shares are recommended to be trimmed rather than bought after a Hold downgrade.
  • Pfizer yields 6.2% but current price assumes materially stronger 2029 profits not yet supported by fundamentals.
  • Advisers recommend a disciplined mid-term profit-taking trade with defined entry, target, and stop.
  • Treasure Global’s subsidiary will build a 1,000-acre, 360 MW AI-enabled solar farm in Malaysia.
  • The US$367 million project includes a 25-year power supply agreement for a data center.
  • The development is projected to generate about US$7.3 million in annual technology revenue and expands the firm's renewable footprint.

Latest Articles

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

Corbus Pharmaceuticals announced FDA clearance to initiate its Phase 3 TEMPO-1 study testing CRB-701, a next-generation antibody drug conjugate targeting Nectin-4, in patients with second-line oropharyngeal squamous cell carcinoma (OPSCC). The study aims to evaluate CRB-701's efficacy and safety compared to current therapies, leveraging promising P…

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

YD Bio Limited announced a six-month pilot program in collaboration with Numia Health to evaluate a cross-border clinical workflow for physician-ordered, blood-based cancer testing for patients in British Columbia, Canada. The pilot aims to assess the scalability of integrating physician access, mobile blood collection, specimen logistics, and labo…

XFLT Proxy Vote: What Shareholders Need to Know About the Liquidity Plan and Discount Management Programs

XFLT Proxy Vote: What Shareholders Need to Know About the Liquidity Plan and Discount Management Programs

XAI Floating Rate & Alternative Income Trust (XFLT) announces a board-approved liquidity plan involving an initial and two contingent tender offers designed to support shareholder value through a Discount Management Program (DMP). Shareholders are urged to vote for the King Street Capital Management sub-advisory agreement enabling these offers. The…

Abundia Global Impact Group Announces Completion of the Process Design Package with Alterra Energy

Abundia Global Impact Group Announces Completion of the Process Design Package with Alterra Energy

Abundia Global Impact Group announced the completion of the Process Design Package (PDP) by Alterra Energy, marking an important engineering milestone for its planned 80,000 tons-per-annum waste plastics-to-fuels and chemicals facility in Baytown, Texas. This milestone allows Abundia to progress its Front-End Engineering Design phase by integrating…

authID and MajorKey Technologies Expand Partnership Through OEM Agreement, Embedding Verified and PrivacyKey Across MajorKey's Identity Security Portfolio

authID and MajorKey Technologies Expand Partnership Through OEM Agreement, Embedding Verified and PrivacyKey Across MajorKey's Identity Security Portfolio

authID announced an expanded OEM agreement with MajorKey Technologies to embed its Verified™, PrivacyKey™, and Proof™ biometric identity verification technologies directly into MajorKey’s identity security offerings. This allows MajorKey to deliver advanced privacy-preserving biometric verification across various high-risk identity workflows beyond…

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

Firefly Neuroscience (NASDAQ: AIFF) and Next Health announced a strategic collaboration to develop a precision cognitive health platform combining Firefly's AI-powered FDA-cleared EEG/ERP brain biomarker system with personalized peptide protocols, such as Epitalon and Semax. This initiative aims to provide objective clinical measures to personalize…

Tesla Agrees to Buy Most Output from Arizona Solar-and-Storage Project

Tesla Agrees to Buy Most Output from Arizona Solar-and-Storage Project

Tesla has entered a long-term power purchase agreement to acquire 90% of the electricity output from Project Sterling, a large solar-plus-storage project in Arizona developed by ContourGlobal and backed by KKR & Co. The facility, scheduled to start operations in 2028, will feature 509 megawatts of peak solar capacity and 360 megawatts of four-hour …

Gold Hovers Around $4,000 as Fed Rate Risk Battles Central Bank Buying

Gold Hovers Around $4,000 as Fed Rate Risk Battles Central Bank Buying

Gold is trading around $4,029, down about 1.17% on the day and roughly 25.4% below six-month highs, as investors weigh a possible Fed rate move against ongoing structural demand from central banks. Technical indicators on daily and weekly charts read Strong Sell, yet heavy central bank purchases and oversold weekly momentum indicators leave scope f…

Trevi Therapeutics to Participate in Upcoming August Conferences

Trevi Therapeutics to Participate in Upcoming August Conferences

Trevi Therapeutics, a clinical-stage biopharmaceutical company developing Haduvio™ for chronic cough related to idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough, announced its management's participation in key August biotech conferences to discuss clinical progress and company strategy.